Thelansis

Non-Metastatic Castration-Sensitive Prostate Cancer (nmCSPC) Market Outlook Thelansis’s “Non-Metastatic Castration-Sensitive Prostate Cancer (nmCSPC) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Non-Metastatic Castration-Sensitive Prostate Cancer (nmCSPC) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China). Key business questions answered: How can drug development and lifecycle management strategies be optimized across G8 markets (US, EU5, Japan, and China)? How large is the patient population in terms of incidence, prevalence, segments, and those receiving drug treatments? What is the 10-year market out...

  Non-Metastatic Castration-Sensitive Prostate Cancer (nmCSPC) Market Outlook Thelansis’s “Non-Metastatic Castration-Sensitive Prostate Cancer (nmCSPC) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Non-Metastatic Castration-Sensitive Prostate Cancer (nmCSPC) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China). Non-Metastatic Castration-Sensitive Prostate Cancer (nmCSPC) Overview Non-metastatic castration-sensitive prostate cancer (nmCSPC) constitutes a transient stage of the disease. It emerges with resistance to castration (manifested by testosterone levels falling below 50 ng/mL) after androgen deprivation therapy (ADT). The abs...

Non-metastatic castration-sensitive prostate cancer (nmCSPC) constitutes a transient stage of the disease. It emerges with resistance to castration (manifested by testosterone levels falling below 50 ng/mL) after androgen deprivation therapy (ADT). The absence of observable metastases in standard imaging scans characterizes this stage. Simultaneously, there is a gradual increase in prostate-specific antigen (PSA) levels, reaching a minimum of 25% higher than the lowest point (nadir) while starting with a PSA level of ≥ 1.0 ng/mL. This increase must be at least 2 ng/mL and verified by a second reading. Nevertheless, the progression of this condition into metastatic disease is a complex process that is not yet fully comprehended. Most individuals diagnosed with non-metastatic castration-resistant prostate cancer (nmCRPC) do not exhibit symptoms or experience only minor ones due to localized treatment effects. In cases where the PSA doubling time is short (< 10 months) and initial PSA ...